Summary

Report Scope
The report examines trends in the global market for AI in clinical trials. It segments the global market by component, phase, deployment mode, therapeutic area and end user. It also provides insights into key emerging trends and potential growth drivers. Components consist of software and services. Deployment mode include cloud, on-premise, and hybrid. Therapeutic areas include cancers, infectious diseases and neurological diseases. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and research and academic institutes.
The report’s regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. It evaluates the impact of AI adoption in clinical trials and the market dynamics, including drivers and challenges. The study concludes with an analysis of leading companies in the market and their product portfolios.
It includes global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

Report Includes
- 56 data tables and 52 additional tables
- In-depth analysis of the global market for artificial intelligence (AI) in pharmaceutical clinical trials
- Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the market’s size and revenue growth prospects, accompanied by a market share analysis by offerings, deployment type, trial phase, therapeutic area, end user and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
- Impact analysis of U.S. tariff laws on AI in the clinical trials market
- Insights derived from Porter’s Five Forces model, as well as a global supply chain analysis
- A look at the regulatory landscape featuring key international and regional regulations and standards for AI adoption
- Evaluation of recent patent activity and key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Company profiles of major players within the industry, including IQVIA, Medidata, Saama, Merative, and Nvidia Corp.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Future Outlook
Macroeconomic Factors
Global GDP Growth
Demographic Factors
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Impact of AI Adoption on Clinical Trials Market
Overview
Use Cases/Case Studies
Use Case 1: Oncology Patient Recruitment
Use Case 2: Accelerating Data Processing in Infectious Disease Vaccine Trials
Use Case 3: Enhancing Patient Retention in Alzheimer's Disease Trials
AI Adoption: Clinical Trials
Adoption Trends at Regional/Country Levels
AI Disruption Trends
Impact of AI on Industry Verticals
Impact of AI on the Value Chain
Market Spending and Investment
Market Spending and Forecasting Analysis
Venture Capital Investment in AI Focused on Clinical Trials
Chapter 3 Market Dynamics
Market Drivers
Need for a Faster Drug Development Process
AI-driven Clinical Trials
Advanced Data Handling for Complex Clinical Input
Market Restraints
Data Privacy and Security Concerns
Regulatory Uncertainties
High Costs and Technical Complexity
Market Opportunities
Accelerated Trials Through Adaptive AI Design
AI-Augmented Remote Patient Monitoring
Chapter 4 Regulatory Landscape
Regulatory Framework
Chapter 5 Emerging Technologies
Overview
Emerging Technologies
Machine Learning for Predictive Analytics and Stratification
Digital Twin Technology
NLP for Extracting Insights from Unstructured Data
AI-Powered Trial Design and Optimization
Blockchain for Secure Clinical Data Management
Decentralized and Virtual Trial Platforms
Remote Monitoring Via Wearable Technologies
Generative AI for Protocol Authoring
Real-World Evidence Integration in Clinical Trials
Cloud-based AI Platforms for Scalable Deployment
Clinical Trial Analysis
Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for AI in Clinical Trials, by Component
Takeaways
Software
Services
Global AI in Clinical Trials Market, by Phase
Takeaways
Phase III
Phase II Trials
Phase I
Phase IV Clinical Trials
Global Market for AI in Clinical Trials, by Deployment Mode
Takeaways
Cloud
On-premise
Hybrid Deployments
Global Market for AI in Clinical Trials, by Therapeutic Area
Takeaways
Oncology
Infectious Disease Clinical Trials
Neurological Diseases
Other Conditions
Global Market for AI in Clinical Trials, by End User
Takeaways
Pharmaceutical and Biotech Companies
Contract Research Organizations
Research and Academic Institutes
Other End Users
Geographic Breakdown
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Overview
Chapter 8 Sustainability in AI in Clinical Trials: ESG Perspective
Sustainability Trends and AI Initiatives
Concluding Remarks
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
AICURE
CONCERTAI
DNANEXUS INC.
INSILICO MEDICINE
INTELLIGENCIA AI
IQVIA
MEDIDATA
MERATIVE
NVIDIA CORP.
PHESI
SAAMA
TEMPUS
TRINETX LLC
TRIOMICS
UNLEARN.AI INC.
Emerging Start-ups/ Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for AI in Clinical Trials, by Region, Through 2030
Table 1 : Real GDP Growth, by Country, 2022-2025
Table 2 : Venture Capital Funding for U.S. Companies on AI for Clinical Trials
Table 3 : VC Investment in AI Focused on Clinical Trials
Table 4 : Regulations Pertaining to AI in Clinical Trials
Table 5 : Clinical Trials Studies
Table 6 : Global Market for AI in Clinical Trials, by Component, Through 2030
Table 7 : Global Market for AI Software in Clinical Trials, by Region, Through 2030
Table 8 : Global Market for Services Related to AI in Clinical Trials, by Region, Through 2030
Table 9 : Global Market for AI in Clinical Trials, by Phase, Through 2030
Table 10 : Global Market for AI in Phase III Clinical Trials, by Region, Through 2030
Table 11 : Global Market for AI in Phase II Clinical Trials, by Region, Through 2030
Table 12 : Global Market for AI in Phase I Clinical Trials, by Region, Through 2030
Table 13 : Global Market for AI in Phase IV Clinical Trials, by Region, Through 2030
Table 14 : Global Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 15 : Global Market for Cloud Deployments of AI in Clinical Trials, by Region, Through 2030
Table 16 : Global Market for On-Premise Deployments of AI in Clinical Trials, by Region, Through 2030
Table 17 : Global Market for Hybrid Deployments of AI in Clinical Trials, by Region, Through 2030
Table 18 : Global Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 19 : Global Market for AI in Oncology Clinical Trials, by Region, Through 2030
Table 20 : Global Market for AI in Infectious Disease Clinical Trials, by Region, Through 2030
Table 21 : Global Market for AI in Neurological Disease Clinical Trials, by Region, Through 2030
Table 22 : Global Market for AI in Clinical Trials for Other Conditions, by Region, Through 2030
Table 23 : Global Market for AI in Clinical Trials, by End User, Through 2030
Table 24 : Global Market for AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, Through 2030
Table 25 : Global Market for AI Used in Clinical Trials by CROs, by Region, Through 2030
Table 26 : Global Market for AI Used in Clinical Trials by Research and Academic Institutes, by Region, Through 2030
Table 27 : Global Market for AI Used by Other End Users in Clinical Trials, by Region, Through 2030
Table 28 : Global Market for AI in Clinical Trials, by Region, Through 2030
Table 29 : North American Market for AI in Clinical Trials, by Component, Through 2030
Table 30 : North American Market for AI in Clinical Trials, by Phase, Through 2030
Table 31 : North American Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 32 : North American Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 33 : North American Market for AI in Clinical Trials, by End User, Through 2030
Table 34 : North American Market for AI in Clinical Trials, by Country, Through 2030
Table 35 : European Market for AI in Clinical Trials, by Component, Through 2030
Table 36 : European Market for AI in Clinical Trials, by Phase, Through 2030
Table 37 : European Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 38 : European Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 39 : European Market for AI in Clinical Trials, by End User, Through 2030
Table 40 : European Market for AI in Clinical Trials, by Country, Through 2030
Table 41 : Asia-Pacific Market for AI in Clinical Trials, by Component, Through 2030
Table 42 : Asia-Pacific Market for AI in Clinical Trials, by Phase, Through 2030
Table 43 : Asia-Pacific Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 44 : Asia-Pacific Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 45 : Asia-Pacific Market for AI in Clinical Trials, by End User, Through 2030
Table 46 : Asia-Pacific Market for AI in Clinical Trials, by Country, Through 2030
Table 47 : MEA Market for AI in Clinical Trials, by Component, Through 2030
Table 48 : MEA Market for AI in Clinical Trials, by Phase, Through 2030
Table 49 : MEA Market for AI in Clinical Trials, by Deployment Mode, Through 2030
Table 50 : MEA Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
Table 51 : MEA Market for AI in Clinical Trials, by End User, Through 2030
Table 52 : MEA Market for AI in Clinical Trials, by Sub-Region, Through 2030
Table 53 : South American Market for AI in Clinical Trials, by Component, Through 2030
Table 54 : South American Market for AI in Clinical Trials, by Phase, Through 2030
Table 55 : South American Market for AI in Clinical Trials, by Deployment Mode,Through 2030
Table 56 : South American Market for AI in Clinical Trials, by Therapeutic Area,Through 2030
Table 57 : South American Market for AI in Clinical Trials, by End User, Through 2030
Table 58 : South American Market for AI in Clinical Trials, by Country, Through 2030
Table 59 : Global Ranking of Players in AI in Clinical Trials Industry, 2024
Table 60 : Strategic Initiatives, 2024 and 2025
Table 61 : Information Sources Used in Preparing this Report
Table 62 : Abbreviations Used in this Report
Table 63 : AiCure: Company Snapshot
Table 64 : AiCure: Product Portfolio
Table 65 : AiCure: News/Key Developments, 2022
Table 66 : ConcertAI: Company Snapshot
Table 67 : ConcertAI: Product Portfolio
Table 68 : ConcertAI: News/Key Developments, 2023 and 2024
Table 69 : DNAnexus Inc.: Company Snapshot
Table 70 : DNAnexus Inc: Product Portfolio
Table 71 : DNAnexus Inc: News/Key Developments, 2024 and 2025
Table 72 : Insilico Medicine: Company Snapshot
Table 73 : Insilico Medicine: Product Portfolio
Table 74 : Insilico Medicine: News/Key Developments, 2023-2025
Table 75 : Intelligencia AI: Company Snapshot
Table 76 : Intelligencia AI: Product Portfolio
Table 77 : IQVIA: Company Snapshot
Table 78 : IQVIA: Financial Performance, FY 2023 and 2024
Table 79 : IQVIA: Product Portfolio
Table 80 : IQVIA: News/Key Developments, 2025
Table 81 : Medidata: Company Snapshot
Table 82 : Medidata: Product Portfolio
Table 83 : Medidata: News/Key Developments, 2023-2025
Table 84 : Merative: Company Snapshot
Table 85 : Merative: Product Portfolio
Table 86 : Nvidia Corp.: Company Snapshot
Table 87 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
Table 88 : Nvidia Corp.: Product Portfolio
Table 89 : Nvidia Corp.: News/Key Developments, 2023–2025
Table 90 : Phesi: Company Snapshot
Table 91 : Phesi: Product Portfolio
Table 92 : Phesi: News/Key Developments, 2022-2025
Table 93 : Saama: Company Snapshot
Table 94 : Saama: Product Portfolio
Table 95 : Saama: News/Key Developments, 2023 and 2024
Table 96 : Tempus: Company Snapshot
Table 97 : Tempus: Product Portfolio
Table 98 : Tempus: News/Key Developments, 2022-2025
Table 99 : TriNetX LLC.: Company Snapshot
Table 100 : TriNetX LLC: Product Portfolio
Table 101 : TriNetX LLC: News/Key Developments, 2025
Table 102 : Triomics: Company Snapshot
Table 103 : Triomics: Product Portfolio
Table 104 : Unlearn.ai Inc.: Company Snapshot
Table 105 : Unlearn.ai Inc.: Product Portfolio
Table 106 : Unlearn.ai Inc.: News/Key Developments, 2022 and 2025
Table 107 : Emerging Startups